MetaCap

Madrigal Pharmaceuticals Inc. (MDGL)

NASDAQ: MDGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD

379.10-17.64 (-4.45%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MDGL stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$5.85
52-week range
353.54 – 615.00
Day range
377.91 – 399.43
Volume / Avg
327.83K / 370.07K
Beta
—

52-week range

$353.54$615.00

MDGL stock today

Shares of Madrigal Pharmaceuticals (MDGL) finished lower on Nov 20 at $379.10, a drop of 4.45% or $17.64 per share, versus the S&P 500's 3.70% decline. At this level, MDGL sits near the bottom of its 52-week range of $353.54 to $615.00: 38.4% below the high, set on Dec 24, 2025 and 7.2% above the low. MDGL is down 34.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 30.8%.

Madrigal Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$5.85), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Madrigal Pharmaceuticals

Company profile

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. William J. Sibold
Headquarters
West Conshohocken, PA
Employees
915
IPO year
2007

Financial highlights

Full financials

In fiscal 2025, Madrigal Pharmaceuticals generated $958.4 million in revenue, up 432.1% from fiscal 2024, its 2nd consecutive year of revenue growth. Madrigal Pharmaceuticals reported a net loss of $288.3 million, compared with a loss of $465.9 million a year earlier. Operating margin was -31.3%.

Madrigal Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$958.40M$180.13M$0$0$0
Growth+432.05%————
Net income$-288.28M$-465.89M$-373.63M$-295.35M$-241.85M
EPS (diluted)$-10.15$-17.31$-17.33$-17.23$-14.63

Analyst forecast

Forecast

Consensus (19 analysts)

strong_buy

Avg. price target

$688.78+81.69%

  • Strong buy 3
  • Buy 15
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $479.00High $962.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$1.83 vs $-1.09
Surprise
+267.89%

MDGL news

All MDGL news

Madrigal Pharmaceuticals peers

Health Care sector
MDGL peer companies
CompanyPrice% ChgMarket capCompare
SYRESpyre Therapeutics Inc.93.47-4.26%$8.88Bvs MDGL
PRAXPraxis Precision Medicines Inc.300.43-3.37%$8.40Bvs MDGL
TGTXTG Therapeutics Inc.63.34-2.37%$9.57Bvs MDGL
SMMTSummit Therapeutics Inc.9.95-5.87%$7.96Bvs MDGL
PTGXProtagonist Therapeutics Inc.121.40-2.11%$7.92Bvs MDGL
RYTMRhythm Pharmaceuticals Inc.112.36-3.80%$7.79Bvs MDGL
ALKSAlkermes plc44.94-2.69%$7.55Bvs MDGL
KNSAKiniksa Pharmaceuticals International plc Class A93.90+0.38%$7.38Bvs MDGL

Indexes, lists and sector

Madrigal Pharmaceuticals stock FAQ

What is Madrigal Pharmaceuticals's stock price today?

MDGL last traded at $379.10 as of Nov 20, 4:00 PM EST, down 4.45% on the day. Prices are delayed at least 15 minutes.

Does Madrigal Pharmaceuticals pay a dividend?

No. Madrigal Pharmaceuticals does not currently pay a regular cash dividend.

Who is Madrigal Pharmaceuticals's CEO?

Mr. William J. Sibold is the chief executive officer of Madrigal Pharmaceuticals Inc., which has about 915 employees.

Has MDGL ever split its stock?

Yes. The most recent MDGL stock split was a 1-for-35 split on Jul 25, 2016.

What is the MDGL 52-week high?

The 52-week high for MDGL is $615.00 and the 52-week low is $353.54. The stock is currently 38.4% below its high.

Compare MDGL